MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.

MacroGenics Inc.

MacroGenics ( ($MGNX) ) has shared an update. On July 1, 2026, MacroGenics, Inc. announced that board member Karen Ferrante, M.D. had notified the ...

MacroGenics announces upcoming board change with director resignation

An announcement from MacroGenics ( ($MGNX) ) is now available. On June 30, 2026, MacroGenics completed the previously announced sale of certain ass...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MGNX	$4.49	+8.98%	1.03M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MGNX	$4.49	+9.0%	1.03M
3
4
5
6

MGNX

MGNX

Get MacroGenics Inc. Data in Excel

Get MacroGenics Inc. Data in Excel